Open AccessCurrent status of photodynamic technology for urothelial cancer
Author(s) -
Inoue Keiji,
Fukuhara Hideo,
Yamamoto Shinkuro,
Karashima Takashi,
Kurabayashi Atsushi,
Furihata Mutsuo,
Hanazaki Kazuhiro,
Lai Hung Wei,
Ogura ShunIchiro
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15193
Subject(s) - photodynamic therapy , cancer , photosensitizer , medicine , porphyrin , cancer research , bladder cancer , lesion , cancer cell , biomarker , pathology , chemistry , biochemistry , organic chemistry
5‐Aminolevulinic acid is a new‐generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating the lesion with a specific wavelength of light to produce fluorescence in the lesion after administration of 5‐aminolevulinic acid, in photodynamic therapy, which induces tumor cell death via production of cytotoxic reactive oxygen species, and in photodynamic screening, in which porphyrin excretion in the blood and urine is used as a tumor biomarker after administration of 5‐aminolevulinic acid. In addition to these applications in urological cancers, 5‐aminolevulinic acid–based photodynamic technology is expected to be used as a novel strategy for a large number of cancer types because it is based on a property of cancer cells known as the Warburg effect, which is a basic biological property that is common across all cancers.